Alsuni Dosage & Drug Information

Concise Prescribing Info

Contents

Sunitinib

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Indications/Uses

Unresectable &/or metastatic malignant GI stromal tumour (GIST) in adults after imatinib mesylate treatment failure due to resistance/intolerance. Advanced &/or metastatic renal cell carcinoma (MRCC) in adults. Unresectable/metastatic well-differentiated pancreatic neuroendocrine tumours (pNET) w/ disease progression in adults.

Dosage/Direction for Use

Adult GIST & MRCC 50 mg once daily for 4 consecutive wk, followed by 2-wk rest period (schedule 4/2) to comprise complete cycle of 6 wk. Max daily dose: 75 mg; or down to 25 mg. pNET 37.5 mg once daily w/o scheduled rest period. Max daily dose: 50 mg. Co-administration w/ potent CYP3A4 inducer (eg, rifampicin) May increase sunitinib in 12.5 mg increments to max of 87.5 mg (GIST & RCC) or 62.5 mg (pNET) daily. Co-administration w/ potent CYP3A4 inhibitor (eg, ketoconazole) May reduce sunitinib in 12.5 mg decrements to min of 37.5 mg (GIST & RCC) or 25 mg (pNET) daily.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EX01 - sunitinib ; Belongs to the class of other protein kinase inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Alsuni cap 12.5 mg

Packing/Price

1's

Form

Alsuni cap 50 mg

Packing/Price

1's

Alsuni

sunitinib

Manufacturer:

Lotus Pharmaceutical Co., Ltd Nantou Plant.